| |
All patients (n = 198)
|
|---|
|
Age, median (IQR)
|
61 (54–66)
|
|
Sex
| |
|
Male
|
163 (82.3%)
|
|
Female
|
35 (17.7%)
|
|
Total pack-years
| |
|
< 10 pack-years
|
84 (42.0%)
|
|
≥ 10 pack-years
|
114 (57.6%)
|
|
Alcohol consumption
| |
|
< 20 drinks per week
|
149 (75.3%)
|
|
≥ 20 drinks per week
|
49 (24.7%)
|
|
Primary site
| |
|
Tonsil
|
108 (54.5%)
|
|
Base of tongue
|
76 (38.4%)
|
|
Soft palate
|
9 (4.5%)
|
|
Vallecula
|
3 (1.5%)
|
|
Indeterminate
|
2 (1.0%)
|
|
Clinical T-stage
| |
|
T1
|
58 (29.3%)
|
|
T2
|
140 (70.7%)
|
|
Clinical N-stage
| |
|
N0
|
21 (10.6%)
|
|
N1
|
52 (26.3%)
|
|
N2
|
125 (63.1%)
|
|
p16 status
| |
|
Positive
|
144 (72.7%)
|
|
Negative
|
28 (14.1%)
|
|
Unknown
|
26 (13.1%)
|
|
Treatment
| |
|
RT
|
39 (19.7%)
|
|
CRT
|
159 (80.3%)
|
|
Radiation laterality
| |
|
Unilateral
|
14 (7.1%)
|
|
Bilateral
|
163 (82.3%)
|
|
Unknown
|
21 (10.6%)
|
|
CT simulation
| |
|
With contrast
|
85 (42.9%)
|
|
Without contrast
|
92 (46.5%)
|
|
Unknown
|
21 (10.6%)
|
|
Chemotherapy regimen
| |
|
Cisplatin
|
135 (68.2%)
|
|
High dose
|
83 (61.4%)
|
|
Weekly
|
52 (38.5%)
|
|
Carboplatinum + 5-fluorouracil
|
14 (7.1%)
|
|
Cetuximab
|
5 (2.5%)
|
|
Other
|
5 (2.5%)
|
- Data are presented as number (%) unless otherwise specified
- RT radiotherapy only, CRT chemoradiation
